Equity Investment: AstraZeneca completed an additional equity investment of $140 million in Cellectis. Cash and Cash Equivalents: $264 million as of December 31, 2024, compared to $156 million as ...

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Recommendation based on AMPLIFY Phase III trial which showed Calquencecombinations demonstrated statistically significant and clinically meaningfulimprovement in progression-free survival vs.

Equity Investment: AstraZeneca completed an additional equity investment of $140 million in Cellectis. Cash and Cash Equivalents: $264 million as of December 31, 2024, compared to $156 million as of ...

Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) ...

Thank you for attending this call today, our analyst briefing for our 2024 Preliminary Results ... times and Oxford Biomedica manufacturing the AstraZeneca COVID vaccine based on an adenovirus.

Discover AstraZeneca's Q1 2025 performance with 10% revenue growth, innovative medicines, and bold 2030 goals.

It is one of the best UK stocks to buy. Overall, 55 hedge funds were bullish on AstraZeneca PLC (NASDAQ:AZN) in Q4 2024, and it was part of 14 billionaire portfolios that had combined stakes worth ...

We recently published a list of Billionaire Israel Englander’s 10 Stock Picks with Huge Upside Potential. In this article, we ...

Tempus AI (TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock ...

Pharmaceutical giant AstraZeneca announced its fourth quarter ... Total revenue for Q4 2024 was $14.9bn (€14.4bn), which was a surge of 24%. Core earnings per share (EPS) came up to $2.09 ...